I ka makahiki 2026, e piʻi ka mākeke botulinum toxin honua i ka US $ 7.9 biliona

Abstract: E hōʻea ka mākeke botulinum toxin honua i $ 7.E hiki i ka 9 biliona e 2026. ʻO ka toxin botulinum he neurotoxin i hana ʻia e Clostridium botulinum, hiki ke pale i ka hoʻokuʻu ʻana o ka acetylcholine a hoʻomaha i ka ʻiʻo.
New York, Iulai 14, 2021 (GLOBE NEWSWIRE) - Ua hoʻolaha ʻo Reportlinker.com i ka hoʻokuʻu ʻana o ka hōʻike "Global Botox Industry"-https://www.reportlinker.com/p0119494/?utm_source=GNW i loko o kahi keʻena hoʻomalu i hana ʻia ma lalo o nā kūlana a hāʻawi ʻia i loko o nā puʻupuʻu therapeutic liʻiliʻi loa, ʻo BTX wale nō ke lawelawe ʻia i loko o ka wahi i hoʻopilikia ʻia.ʻO ka ulu ʻana o ka mākeke honua e alakaʻi ʻia e ka piʻi nui o ka noi no ka lāʻau lapaʻau / therapeutic a me nā noi cosmetic.Ke hoʻonui nui ʻia nei ka ʻae ʻana o ka maka (e like me BTX) i ka nani o ka helehelena makua, a ʻo ka ʻae ʻia o ka therapeutic BTX e mālama i kahi ākea ākea o nā hōʻailona e manaʻo ʻia e hoʻoulu i ka hoʻonui ʻana i ka mākeke.Ke hoʻomau nei ka hoʻomohala ʻana a me ka hoʻomaka ʻana o nā huahana hou e hoʻomaikaʻi ai i ka hoʻopiʻi aesthetic, a me ka piʻi nui ʻana o ka noi no nā lāʻau lapaʻau liʻiliʻi invasive a me nā noi therapeutic, ke koi nei i ka noi mākeke.Ma ke kahua o ka neuromuscular therapy, hoʻohana ʻia ka hoʻohana ʻana i ka botulinum toxin e ka piʻi ʻana o nā maʻi e pili ana i nā haʻuki a me ka piʻi ʻana o ka nui o nā maʻi me nā spasms muscle.Eia kekahi, nā hōʻailona hou o ka botulinum toxin, e like me ka mālama ʻana i ka nystagmus, stridor, palatine myoclonus, scoliosis, co-spasm ma hope o ka brachial plexus neuropathy (pili i ka hānau ʻana) a me ka gait freezing (Parkinson), kōkua i ka hoʻoikaika ʻana i ka ulu ʻana o keia kahua.I ka wā o ka pilikia COVID-19, ua manaʻo ʻia ka mākeke honua no ka botulinum toxin i 2020 he 4.9 biliona kālā ʻAmelika, a ke manaʻo ʻia nei e hōʻea i ka 7.9 biliona kālā ʻAmelika i hoʻoponopono hou ʻia e 2026, kahi i manaʻo ʻia he 8.2 biliona kālā ʻAmelika i ka wā wā kālailai.% Hoʻohui ʻia ka ulu ʻana o ka ulu makahiki.ʻO ka Category A kekahi o nā māhele mākeke i loiloi ʻia i ka hōʻike.Manaʻo ʻia ma ka hopena o ka manawa loiloi, e piʻi ka nui o ka ulu ʻana o ka makahiki i ka 8.2% a hiki i ka USD 8.5 biliona.Ma hope o ka nānā pono ʻana i ka hopena o ka ʻoihana o ka maʻi maʻi a me ka pilikia o ka hoʻokele waiwai i hoʻāla ʻia, ua hoʻoponopono hou ʻia ka ulu ʻana o ka māhele mākeke B i kahi hoʻonui hou o ka ulu ʻana o 6.9% i nā makahiki 7 e hiki mai ana.Hiki ke hoʻohana ʻia ka Botulinum toxin type A no ka mālama ʻana i nā maʻi o ka neʻe ʻana, ka hana ʻole o ke kaula leo a me ka momona, a me ka maʻi maʻi ʻōpū.Hoʻohana nui ʻia ka Botulinum toxin type A i ka mālama ʻana i ka maʻi spasm cerebral palsy a me ka maʻi neurogenic bladder i nā keiki, kahi e hoʻoikaika ai i ka ulu ʻana o ka botulinum toxin type A. Hoʻohana ʻia ke ʻano B no nā maʻi like ʻole e pili ana i ka ʻiʻo.Ua ʻae ʻia ʻo Botulinum neurotoxin type B e ka FDA i ka makahiki 2000 no ka mālama ʻana i ka dystonia cervical makua e hōʻemi i ke koʻikoʻi o ke kūlana poʻo kūlohelohe a me ka ʻeha ʻāʻī e pili ana me ka cervical dystonia.ʻO ka mākeke US ma 2021 ka mea i manaʻo ʻia he US $ 3.1 biliona, ʻoiai ʻo Kina e manaʻo ʻia e hōʻea i ka US $ 665 miliona e 2026. ʻO ka US botulinum toxin market i manaʻo ʻia he US $ 3.1 biliona e 2021. ʻO Kina ka lua o ka hoʻokele waiwai nui ma ka honua.Ua manaʻo ʻia e 2026, manaʻo ʻia ka nui o ka mākeke e hōʻea i 665 miliona US kālā, me ka nui o ka ulu ʻana o ka makahiki he 14.8% i ka wā o ka loiloi.ʻO nā mākeke ʻāina kaulana ʻē aʻe ʻo Iapana a me Kanada, ka mea e manaʻo ʻia e ulu e 8.1% a me 6.9%, i ka wā o ka loiloi.Ma ʻEulopa, manaʻo ʻia e ulu ʻo Kelemania i kahi ulu ulu makahiki ma kahi o 9.1%.ʻO ʻAmelika Hui Pū ʻIa ka mākeke kūloko nui loa, ma muli o ka hoʻonui mau ʻana i nā ʻae no nā hōʻailona therapeutic hou.Eia kekahi, ʻo ka piʻi nui ʻana o ka nānā ʻana i ka hoʻomaikaʻi ʻana i ka helehelena, ka piʻi ʻana o ka loaʻa kālā o ka poʻe, a me ka piʻi ʻana o ka noi no ka hoʻomaʻamaʻa cosmetic i kōkua pū i ka ulu.ʻO ka piʻi nui ʻana o ka hoʻomaʻamaʻa non-invasive a i ʻole ka liʻiliʻi invasive cosmetic i kōkua i ka ulu ʻana o ka mākeke Botox ma United States.Ma muli o ka nui o nā mea hana cosmetic, hāʻawi pū ʻo ʻEulopa i nā manawa kūpono no ka mākeke botulinum.ʻO ka hoʻomaikaʻi wikiwiki ʻana i nā kūlana socio-economic a me ka piʻi ʻana o ka mākaʻikaʻi olakino, ʻoi aku hoʻi ma nā ʻāina ʻĀsia, hāʻawi i kahi manaʻo maikaʻi no ka hoʻomohala ʻana o ka botulinum toxin ma ka ʻāina ʻo Asia-Pacific.E koho i ka mea hoʻokūkū (28 i koho ʻia i ka huina)
E heluhelu i ka hōʻike piha: https://www.reportlinker.com/p0119494/?utm_source=GNW I. ʻO ke ala ʻelua.Hōʻuluʻulu Manaʻo 1. Ka ʻike ʻana o ka mākeke Influencer market insight in the trajectory of the world market ʻO ka hopena o Covid-19 a me ka hōʻemi ʻana o ka honua holoʻokoʻa COVID-19 interruption e pili ana i ka mālama mālama virtual botulinum toxin i waena o nā keʻena nani COVID-19 e lawe i ka maʻi. Nā hana pale E hoʻemi i ka pilikia o ka laha ʻana o ka maʻi maʻi COVID-19 Papa 1: Ma muli o ka maʻi maʻi COVID-19 o Malaki 2020, ua piʻi ka pākēneka o ka hoʻouka ʻana o ka migraine.Hōʻike ka hoʻopili ʻana o COVID-19 i ka mea nui o ka botulinum toxin therapy no nā maʻi pili.Nānā nā mea noiʻi i ka botulism Bacillus toxin ma ke ʻano he koho lapaʻau kūpono no ka hoʻēmi ʻana a me ka hoʻokele.ʻO ka maʻi COVID-19 me ka botulinum toxin: Hoʻomaka i nā manaʻo no ka mālama ʻana i ka noi BTX alakaʻi i nā mea hoʻonaninani BTX e hoʻoikaika mālie i ka mākeke BT: ma kahi pōkole Kiʻi 2: ʻO ka ʻiʻo ma nā ʻāina i koho ʻia Ka pākēneka o nā kauka lapaʻau e hana ana i ka ʻoki ʻana i ka botulinum toxin: Manaʻo i ka botulinum. ka mākeke toxin ma nā wahi i kūkulu ʻia i ka makahiki 2019. E hoʻomohala i ka mākeke e hoʻolaha iā Futu e ulu hou i ka ʻāina hoʻokūkū.ʻO ka mākeke botulinum toxin he mea hoʻokūkū nui.Kiʻi 3: Ke alakaʻi nei ka mākeke botulinum toxin honua i ka māhele mākeke o Enterprise: ʻO nā huahana toxin botulinum i koho ʻia no ka ʻae ʻia ma 2019. Ke komo nei nā hui honua i ka mākeke BT waiwai i nā maka o Fray Pharmaceuticals.Kūleʻa nā ʻano like ʻole BTX i ke alakaʻi o ka botulinum toxin.ʻO ka nele o nā ʻokoʻa ma waena o nā huahana BTX i ʻae ʻia ʻO ka hoʻohālikelike ʻana o nā neurotoxins nui-Botox, Dysport a me Xeomin e hoʻohālikelike ʻia e ka palekana a me ka pono.Ua ʻae ʻia ʻo Botox®, Dysport® a me Xeomin® e ka hōʻailona a me ka makahiki o ka ʻae ʻia.ʻAe ʻia ʻo Botox a me nā hōʻailona Botox ma nā wahi kikoʻī i ʻae ʻia ʻo Therapeutics i ʻAmelika Hui Pū ʻIa hilinaʻi ʻo Ipsen iā Dysport Xeomin® Merz a me nā huahana ʻē aʻe no nā hōʻailona hou o ka ulu ʻana o ka wā e hiki mai ana.Nā hana makeke hou 2. E nānā i nā mea i koho ʻia 3. Nā ʻano mākeke a me nā mea hoʻokele Ke hoʻonui nei i ka noi no nā lāʻau lapaʻau non-invasive no ka mākeke BTX He hōʻailona maikaʻi ia Annex 4: Global non-surgical cosmetic surgery (2018) ʻO ka nui o ka ʻoki ʻana i nā toxin: ʻo ka hopena i makemake ʻia no ka mākeke injection facial Kiʻi 5: Cosmetic botulinum toxin surgery i hana ʻia ma ka honua holoʻokoʻa (2019): Pakēneka o ka haʻihaʻi ʻana o ka helu o nā millennials' ʻoki kāne kāne: Botulinum toxin prevalence demographic data Figure 6: Global cosmetic botulinum toxin surgery in 2019): Haʻihaʻi pākēneka o nā ʻokiʻoki e ka pūʻulu makahiki ma ka pūʻulu makahiki Ka pākēneka wahi lapaʻau a me Opportunity botulinum toxin therapeutic application hoʻohana a me nā hōʻailona Papa 7: Global therapeutic BTX neurotoxin market segmentation by treatment indication (2019) Botulinum toxin ke kumu gula no ka mālama ʻana. o nā pilikia koʻikoʻi.Hoʻonui i ka nui o nā hōʻailona musculoskeletal : ʻAʻole i hoʻokō ʻia ke koi olakino hiki ke hoʻoikaika i ka hoʻohana ʻana i waho-label: hopohopo a paipai paha?ʻO ka lāʻau hoʻohui: kahi pā pālua kūleʻa i ka botulinum toxin: hiki ke hoʻohana i ka mālama ʻana i nā maʻi niho.Nā hopena aesthetic no ka wā pōkole: kahi hihia ʻoihana ikaika no ka hoʻoponopono ʻana.ʻO nā ʻōnaehana hoʻoheheʻe hou no nā mea hoʻohālikelike botulinum toxin kiʻekiʻe.ʻOi aku ka lōʻihi o ke ola a me ka hoʻonui ʻia ʻana o ka loaʻa kālā hoʻohana hoʻokahi e hoʻoikaika i ke kūʻai ʻana i nā mea hoʻonaninani BTX Papa 8: Ka manaʻolana o ke ola ma ka hānau ʻana (i nā makahiki) no ka heluna kanaka ma nā ʻāina i koho ʻia Mahele 9: Manaʻolana ola ma ka hānau ʻana (i nā makahiki) no nā kāne a me nā wahine ma ka ʻāina. ʻO ka piʻi ʻana o ka hoʻolimalima mālama olakino ua hoʻoulu i ka noi no BTX no nā noi therapeutic.ʻO nā lilo mālama ola i kēia manawa (CHE) ma ke ʻano he pākēneka o GDP (%): 2017 Chart 10: 2017-2023 World healthcare expenditure (US$ billion) ) Nā pilikia a me nā pilikia Nā hopena ʻino: Ke pane ʻana i ka pilikia o ka luku immunogenic.Ka hoʻokō ʻana o ka maʻi Antigenicity: He pilikia i ka hoʻomohala ʻana i ka lāʻau.Nā hopena ʻaoʻao kūpono ʻole: A. ʻO nā mea pale nui i ka holomua.B. Nā hoʻoponopono koʻikoʻi a me ka lohi i ka ʻae ʻana o ka mākeke.ʻO nā kumukūʻai huahana kiʻekiʻe e hoʻokūkū i ka manaʻo kānalua o ka mea kūʻai aku no ka ulu ʻana o ka mākeke: ka lanakila ʻana i ka pilikia nui o ka hoʻomāinoino holoholona: ʻāpana o ka botulinum toxin hoʻāʻo 4. Global market outlook table 1: kūlana honua a me ka nānā ʻana o ka botulinum toxin Geographic region-United States, Canada, Japan , Kina, ʻEulopa, ʻAsia Pākīpika, ʻAmelika ʻAmelika a me ke koena o ka ʻike kūʻokoʻa kūʻokoʻa o ka honua i nā kūʻai makahiki (i loko o nā tausani o nā kālā US) a me ka hoʻohui ʻana i nā pākēneka o ka ulu makahiki mai 2020 a 2027 Papa 2: World mōʻaukala o Botox e ka ʻāina ʻāina Toxins -United States, Canada, Japan, China, Europe, Asia Pacific, Latin America and other world market-Independent analysis of 2012-2019 annual sales (i loko o na tausani o US dollars) and compound annual growth rate percentage Table 3: World 15-Percentage o nā makahiki toxin botulinum e ka ʻāina ʻāina-2012, 2020 a me 2027 ʻo ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, Latin America a me ke koena o ka mākeke kūʻai kūʻai kūʻai o ka honua.n ble 4: Ma ka nānā 'ana i kēia manawa a me ka wā e hiki mai ana o ka honua A-class e ka'āina'āina-United States, Canada, Japan, China, Europe, Asia Pacific, Latin America a me nā mākeke ʻē aʻe o ka honua-Ka nānā kūʻokoʻa kūʻai kūʻai makahiki ma nā tausani o Nā kālā US mai 2020 a 2020 2027 a me % CAGR Papa 5: Papa A World History Review e Geographic Region-United States, Canada, Japan, China, Europe, Asia Pacific, Latin America a me nā mākeke honua ʻē aʻe-Nānā kūʻokoʻa kūʻai kūʻai makahiki i nā tausani. o nā kālā US ma luna o nā makahiki 2012 Makahiki a 2019 a% CAGR Papa 6: He 15-makahiki ka nānā ʻana no ka honua e ka ʻāina ʻāina-2012 United States, Canada, Japan, China, Europe, Asia Pacific, Latin America a me ke koena o ka ka pākēneka haʻihaʻi kūʻai honua, 2020 Makahiki a me 2027 Papa 7: Ka nānā ʻana i kēia manawa a me ka wā e hiki mai ana o ka honua B-class e ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, Latin America a me nā kūlanakauhale ʻē aʻe o ka honua Field- Ka nānā kūʻokoʻa o nā kūʻai makahiki (i nā tausani of US dollars) 2020 a 2027 a me% CAGR Papa 8: World History Category B Review by Geographic Region-United States, Canada, Japan, China, Europe, Asia Pacific, Latin America A me nā mākeke ʻē aʻe i ka nānā ʻana kūʻokoʻa honua a me% CAGR o nā kūʻai makahiki (tausani dala) mai 2012 a i 2019 Papa 9: Māhele B 15-makahiki World Outlook e Geographic Region-2012, 2020 a me 2027 United States, Canada, Iapana, Breakdown of sales value percentages in China, Europe, Asia Pacific, ʻAmelika ʻAmelika a me nā mea ʻē aʻe o ka honua Papa 10: Ka nānā ʻana i kēia manawa a me ka wā e hiki mai ana o nā lāʻau lapaʻau i ka honua e ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, Latin America a me ke koena o ka ʻike kūʻokoʻa honua. o nā kūʻai makahiki (tausani dala) a me ka helu o ka ulu ʻana o ka makahiki mai 2020 a 2027 11: He loiloi o ka mōʻaukala honua o nā therapeutics e ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific Regions, Latin America a me ka koena o ka honua-indKa nānā 'ana o ka makahiki 2012-2019 kū'ai makahiki (i loko o nā kaukani 'Amelika) a me ka hui 'ana i ka helu o ka ulu 'ana o ka makahiki Papa 12: World 15-makahiki outlook e Therapeutics by geographic region-2012, 2020 and 2027 Sales Value Percentage Breakdown in the United States, Canada , Iapana, Kina, ʻEulopa, Asia Pākīpika, ʻAmelika Latina a me ke koena o ka honua.Papa 13: World Aesthetics Status and Future Analysis by Geographic Region-United States, Canada, Japan, China, Europe , Asia-Pacific, Latin America and other world market-independent analysis and% CAGR o ke kuai makahiki (i na tausani o na dala US) mai 2020 a i 2027 Papa 14: World History Review Aesthetics e Geographic Region-United States, Canada, Japan, China, Europe, Asia Pacific, Latin America a me ke koena o ka honua-Kuʻokoʻa ka nānā ʻana o ke kūʻai aku (i nā tausani o nā kālā US) a % CAGR mai 2012 a 2019 Papa 15: World 15-Aesthetic makahiki hiʻohiʻona e ka ʻāina ʻāina- Ka hoʻokaʻawale ʻana o ke kūʻai aku o ka waiwai kūʻai pākēneka ma United States, Canada, Japan, China, Europe, Asia Pacific, Latin America a me ke koena o ka honua. 2012, 2020 a me 2027. Papa 16: World Current and Future Analysis Specialties and Dermatology Clinics by Geographic Region-United States , Canada, Japan, China, Europe, Asia Pacific, Latin America and other world market-independent analysis of annual sales (i loko o nā tausani o nā kālā US) a me ka hoʻohui ʻana i ka nui o ka ulu makahiki mai 2020 a 2027 Papa 17: Hōʻikeʻike moʻolelo o ka honua e nā loea a me nā dermatology clinics e ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, Latin America a me nā mākeke ʻē aʻe ma ka honua-kūʻokoʻa ka nānā ʻana a me ka% CAGR papa o nā kūʻai makahiki (tausani kālā) mai 2012 a 2019 18: 15-makahiki outlook no ka honua loea a me dermatology clinics e geographic region-2012, 20 A breakdown of sales value percentages in the United States, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, Latin America a me ke koena o ka honua ma 20 a me 2027 Papa 19: Ke kūlana honua a me ka nānā ʻana i ka wā e hiki mai ana o nā halemai a me nā keʻena ma ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada , Iapana, Kina, ʻEulopa, ʻAsia Pākīpika, ʻAmelika ʻAmelika a me nā mākeke ʻē aʻe i ka ʻike kūʻokoʻa kūʻokoʻa o ka honua i nā kūʻai makahiki (i loko o nā tausani o nā kālā ʻAmelika) mai 2020 a 2027 a me %C AGR Papa 20: Nā halemai a me nā keʻena ma ka ʻāina ʻāina World History Review-United States, Canada, Iapana, Kina, ʻEulopa, ʻAsia Pākīpika, ʻAmelika ʻAmelika, a me nā mākeke ʻē aʻe i ka honua-Ka nānā kūʻokoʻa kūʻokoʻa o ke kūʻai ʻana i nā makahiki he mau tausani o ʻAmelika mai 2012 a 2012, 2019 a me% CAGR Papa 21: Ma ka ʻāina ʻāina 15-makahiki outlook no nā halemai a me nā keʻena lapaʻau ma ka honua-2012 United States, Canada, Iapana, Kina, Europe, Asia Pacific, Latin America a me ke koena o ka honua ma ke ʻano he pākēneka o ka waiwai kūʻai, 2020 a me 2027 Papa 22: Nā hopena hope ʻē aʻe e ka ʻāina honua. ʻO ka loiloi o kēia manawa a me ka wā e hiki mai ana-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, ʻAsia Pākīpika, ʻAmelika ʻAmelika a me nā mākeke honua ʻē aʻe-Ka ʻike kūʻokoʻa kūʻokoʻa o nā kūʻai makahiki makahiki (USD) Millennium a me% CAGR mai 2020 a 2027 Papa 23: Ma kahi loiloi ʻO ka mōʻaukala honua o nā hoʻohana hope ʻē aʻe e ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, ʻAmelika ʻAmelika a me nā mākeke ʻē aʻe i ka honua-Ka helu kūʻokoʻa kūʻokoʻa makahiki o 2012 kūʻai i nā tausani o nā kālā US rough 2019 a % CAGR Papa 24 : World 15-makahiki outlook nonā mea hoʻohana hope ʻē aʻe e ka ʻāina ʻāina-ʻAmelika Hui Pū ʻIa, Kanada, Iapana, Kina, ʻEulopa, Asia Pacific, Latin America, a me ke koena o ka pākēneka o ka waiwai kūʻai o ka honua i nā makahiki i hoʻokaʻawale ʻia ma 2012, 2020, a me 2027 mau mākeke. ʻO ka manawa kūpono o nā mea hoʻonaninani BTX ma ka mākaʻikaʻi o ka mākeke US Papa 11: ʻO ka māhele makahiki o ka ʻokiʻoki botulinum toxin i hana ʻia ma ʻAmelika Hui Pū ʻIa i 2019 Papa 12: ʻO ka hāʻawi ʻana i ke kāne o ka hōʻoki toxin botulinum i hana ʻia ma ʻAmelika Hui Pū ʻIa (2019) Ua hoʻonui ʻia ka noi no nā lāʻau lapaʻau e hōʻike ana i ka Plastic Surgery i ka BTX Market: Facts and Figure Figure 13: Number of surgical and non-surgical cosmetic procedures in the United States in 2000, 2018 and 2019 ('000) Figure 14: Top 5 cosmetic surgery in the United States-Number of surgeries done i 2019 ( 000 kekona) Ka helu ʻana i ka Annex 15: ʻO nā kaʻina hana cosmetic non-surgical kiʻekiʻe ma United States-ma ka helu o nā hana i hana ʻia ma 2019 (?000 mau manawa) Ka helu ʻana EXHIBIT 16: ʻO ka helu o nā toxins botulinum i hoʻokō ʻia ma ʻAmelika Hui Pū ʻIa: ʻO nā pēpē pēpē kahiko i 2000, 2016 a me 2019 i hoʻolaha i ka ʻoihana nani. 14, 15-24, 25-59, a me 65+ mau pūʻulu makahiki BIT 18: ʻAmelika ʻĀkau o ka poʻe ʻelemakule ma ka pūʻulu makahiki: 1975-2050 Hoʻonui ke kahua kauka i hoʻonui ʻia i ka ulu ʻana o ka manawa BTX e ʻimi nei i ka ulu ʻana Nā manawa e ʻae i nā hōʻailona mālama lāʻau botulinum toxin ma United States. ma ka makahiki o ka ʻae ʻia ʻO Neurogenic OAB: loaʻa nā manawa kūʻai waiwai ʻo BTX nā huahana hoʻokūkū hoʻokūkū a me nā mea hoʻopihapiha pili i ka mākeke botulinum toxin cosmetic Kiʻi 19: US botulinum toxin Māhele mākeke o nā māka alakaʻi mākeke: E hoʻokūkū ikaika ʻo Dysport me ka botulinum toxin i ka lāʻau lapaʻau. kahua ma 2019. Papa 25: Ka nānā 'ana a me ka wā e hiki mai ana o nā huahana botulinum toxin i ka United States-Type A a me Type B-Sales mai 2020 a i 2027 Ho'oka'awale kū'oko'a a me ka hui makahiki.l ka ulu ana o ka huina (i na tausani o na dala US) Papa 26: Ka loiloi moolelo o na hua toxin botulinum ma Amerika Huipuia-Ke ano A a me ke ano B makeke-Ka helu kuokoa o na kuai makahiki ma United States mai 2012 a 2019 i na tausani o kālā a me% CAGR Papa 27: US 15-makahiki botulinum toxin ma ka huahana-breakdown pakeneka f 2012, 2020, a me 2027 type A a me B kuai waiwai Papa 28: I keia manawa a me ka wā e hiki mai ana o ka US botulinum toxin Analysis-Therapeutics and Aesthetics- ʻIke kūʻokoʻa kūʻokoʻa o ke kūʻai aku i kēlā me kēia makahiki (i nā kaukani US) a me% CAGR mai 2020 a 2027 Papa 29: Ka loiloi mōʻaukala o ka hoʻohana ʻana i ka botulinum toxin ma United States-Therapeutics and Aesthetics Market-2012 i ka loiloi kūʻokoʻa a me ka% CAGR o ke kūʻai aku 2019. (i loko o nā tausani o nā kālā ʻAmelika) Papa 30: Nā manaʻo no ka hoʻohana ʻana i ka botulinum toxin i ʻAmelika Hui Pū ʻIa i 15 mau makahiki-Pakeneka o ka haʻihaʻi ʻana o nā mea lapaʻau a me nā mea kūʻai aku cosmetology ma 2012, 2020 a me 2027 Papa 31 : ʻO ka botulin hoʻohana hope a me ka wā e hiki mai ana.um toxin analysis in the United States-special and dermatological clinics, hospitals and clinics, and other end-use-independent analysis of annual sales (i loko o na tausani o US dollars) and% CAGR from 2020 to 2027 Table 32: US Botox Historical review of Bacillus toxin ma ka hoʻohana hope-Specialty and dermatology clinics, hospitals and clinics, and other end-use markets-Independent analysis of sales (i nā tausani o US dollars) and% CAGR from 2012 to 2019 Table 33: United States 15 Prospects for end- hoʻohana i ka botulinum toxin i ka makahiki 2016-pakeneka o ka haʻihaʻi ʻana o ka waiwai kūʻai no nā keʻena kūikawā a me nā dermatology clinics, nā halemai a me nā keʻena lapaʻau, a me nā mea hoʻohana hope ʻē aʻe ma 2012, 2020 a me 2027. Canada Papa 34: ʻO ka botulinum toxin o Kanada e ka huahana ʻĀpana A me ka wā e hiki mai ana. ʻAno B-I loko o nā makahiki ʻIke kūʻokoʻa kūʻai kūʻai makahiki (i nā kaukani US) mai 2020 a i 2027 a me% CAGR Papa 35: ʻO ka loiloi mōʻaukala o ka botulinum toxin e ka huahana ma Kanada-Type A a me Type B markets-Sales from 2012 to 2019 Kūʻokoʻat ka nānā ʻana o ka nui (i nā tausani o nā kālā US) a me% CAGR Papa 36: ʻO ka 15-makahiki outlook ʻo Botulinum toxin ma ka huahana-breakdown o ke ʻano A a me ke ʻano B kūʻai waiwai ma 2012, 2020, a me 2027 Papa 37: Botulinum ka loiloi toxin no nā noi o kēia manawa a me ka wā e hiki mai ana ma Kanada-Therapeutics a me Aesthetics-Kuʻokoʻa kūʻokoʻa o ke kūʻai ʻana i nā makahiki he mau tausani kālā mai 2020 a 2027 a me% CAGR Papa 38: Ka loiloi mōʻaukala o nā noi botulinum toxin ma Kanada -Therapeutic a me ka mākeke nani-Ka nānā kūʻokoʻa a pākēneka hui makahiki ulu ulu o ke kuai makahiki ma na tausani o US dala mai 2012 a hiki i 2019 Papa 39: Manawa no ka botulinum toxin noi ma Kanada i 15 makahiki-Lapaau ma 2012, 2020 a me 2027 Pakeneka o ke kuai ana o na laau lapaau a me na laau lapaau ma ka waiwai Papa 40. : Ka nānā 'ana a me ka wā e hiki mai ana o ka ho'ohana hope 'ana o ka botulinum toxin ma Kanada-'oihana a me dermatological clinics, halemai a me na halemai a me na hoohana hope 'ole-ke kuai makahiki mai 2020 a 2027 (mau tausani okālā) Papa 41: He loiloi mōʻaukala o ka botulinum toxin ma ka hoʻohana hope ʻana ma Kanada-kūikawā a me nā keʻena dermatology, nā halemai a me nā keʻena lapaʻau, a me nā mākeke hoʻohana hope ʻē aʻe-ka nānā ʻana kūʻokoʻa o nā pākēneka a me ka nui o ka ulu ʻana o ka makahiki Papa 41: He mau tausani kālā) a ka nānā ʻana kūʻokoʻa o nā pākēneka o ka ulu ʻana o ka makahiki Papa 42: ʻO ka 15-makahiki botulinum toxin outlook o Kanada no ka hoʻohana hope-2012, 2020 a me 2027 loea a me nā keʻena dermatology, nā halemai a me nā keʻena, a me nā pākēneka kūʻai waiwai hoʻohana hope ʻē aʻe. Nā kaʻina hana hoʻomaʻemaʻe non-surgical ma Iapana (2019): Haʻihaʻi pākēneka Ka helu o nā hana ma ke ʻano o ka hana Ka pākēneka o nā hana Papa 43: Ka nānā ʻana i kēia manawa a me ka wā e hiki mai ana o ka botulinum toxin e ka huahana ma Iapana-Type A a me Type B -Ka helu kūʻokoʻa o nā kūʻai makahiki ( kaukani dala) a me ka pakeneka ulu makahiki hui mai 2020 a i 2027. Papa 44: Ka loiloi mōʻaukala o nā huahana toxin botulinum Iapana-Makeke A me Type B-Kuai mai 2012 a2019 (Nā kaukani ʻAmelika) a me ka nānā ʻana kūʻokoʻa o ka pākēneka hui ʻana i ka ulu ʻana o ka makahiki Papa 45: 15-makahiki outlook no Japanese botulinum toxin huahana-breakdown pakeneka ma 2012, 2020 a me 2027 Type A a me B waiwai kūʻai Papa 46: ʻIke Kepani o kēia manawa. botulinum toxin no ka hoʻohana ʻana a me nā noi e hiki mai ana-Therapeutics and aesthetics-Ka nānā kūʻokoʻa kūʻai kūʻai makahiki o s a me% CAGR i mau tausani kālā mai 2020 a 2027 Papa 47: Ka loiloi mōʻaukala o nā noi botulinum toxin ma Iapana-Lapaʻau a me ka mākeke nani-2012-2019 makahiki i loko o nā tausani o nā kālā ʻAmelika Ka nānā ʻana kūʻokoʻa o ke kūʻai aku a me ka% CAGR Papa 48: Ke noi ʻana i ka botulinum toxin 15 mau makahiki o Iapana-Paneka ka haki ʻana o ka therapeutic a me ka waiwai kūʻai waiwai ma 2012, 2020 a me 2027 Papa 49: ʻO ka botulinum hoʻohana hope a me ka wā e hiki mai ana. Toxin Analysis-Specialty and dermatology clinics, hospitals and clinics, and other end-use-Independent analysis of annual sales (thanks dollars) and compound annual growth percmai 2020 a 2027 Papa 50: Ka moʻolelo o ka hoʻohana hope ʻana i ka botulinum toxin ma Iapana Review-Specialty and dermatology clinics, hospitals and clinics, and other end-use markets-Hoʻoponopono kūʻokoʻa o nā kūʻai makahiki (i nā kaukani US) a me nā pākēneka CAGR mai 2012 a hiki i 2019 Papa 51: 15-makahiki hope-hoʻohana botulinum toxin o Iapana Prospects-pakeneka emi i ka waiwai o nā kauka lapaʻau a me dermatology clinics, halemai a me nā keʻena kino, a me nā mea kūʻai hoʻohana hope ma 2012, 2020 a me 2027. China market overview The upward ʻO ke ʻano o ka mākeke injection facial e kūpono i ka hoʻonui ʻana o ka mākeke o Botox i ʻae ʻia i ke ʻano hoʻoponopono i loaʻa i ka Toxin injections ke alakaʻi i ka mākeke ma ka hoʻokūkū o Kina no nā mea komo i ka mākeke botulinum toxin: 2019 Papa 52: ʻO ka loiloi botulinum toxin o Kina i kēia manawa a me ka wā e hiki mai ana. A a me ke ʻano B-kūʻai mai 2020 a 2027 Papa 53: Ka loiloi mōʻaukala o ka botulinum toxin o Kina e nā huahana-Type A a me Type B market-2012-2019 kūʻai makahiki (i nā kaukani US) Thiki i ka 54: Kina 15-makahiki botulinum toxin prospects ma ka huahana-waiwai breakdown pākēneka 2012, 2020, a me 2027 kūʻokoʻa kālailai o ka pakeneka o ka makahiki ulu ulu Papa 54: kuai o Type A a me Type B ma 2012, 2020, a me 2027 Papa 55 : China Botulinum toxin analysis no ka manawa a me ka wā e hiki mai ana-Therapeutics and Aesthetics ics-Independent analysis of annual sales in thousands of dollars from 2020 to 2027 and% CAGR Table 56: Historical Review of Botulinum Toxin Application in China-Treatment and beauty market-independent ka nānā ʻana o ke kūʻai ʻana i nā makahiki he mau kaukani US mai 2012 a i 2012. 2019 a me% CAGR Papa 57: ʻO ka noi ʻana o ka botulinum toxin 15 mau makahiki o Kina-kūʻai waiwai o nā lāʻau lapaʻau a me nā lāʻau nani i ka makahiki 2012, 2020 a me 2027 Pakeneka o ka haʻihaʻi ʻana o ka papa 58: ʻO ke kūlana o kēia manawa a me ka nānā ʻana i ka wā e hiki mai ana o ka hoʻohana hope ʻana o ka botulinum toxin ma Kina-kūikawā a me nā keʻena dermatology, nā halemai a me nā keʻena lapaʻau, a me nā mea hoʻohana hope-kūʻokoʻa i nā kūʻai makahiki (i nā kaukani US doll.ars) mai 2020 a i 2027 Ka ʻikepili a me ka% CAGR Papa 59: ʻO ka loiloi mōʻaukala o ka botulinum toxin hope-hoʻohana kūikawā a me nā keʻena dermatology, nā haukapila a me nā keʻena, a me nā mākeke hoʻohana hope-2012-2019 kūʻai makahiki (tausani kālā) a me ka hui. makahiki ulu pākēneka pākēneka kālailai papa 60: Bo ka 15-makahiki outlook no Kina e like me ka loa Tulinum toxin ma hope-hoʻohana papa helu-2012, 2020 a me 2027 i ka waiwai o ke kuai i loko o ka loea a me ka dermatological clinics, halemai a me na halemai, a me kekahi hopena. -hoʻohana ma ke ʻano he pākēneka o ka haki ʻana o nā kūʻai ʻana i ka mākeke ʻEulopa i ka ʻae ʻana a me nā hōʻailona o ka botulinum toxin i nā ʻāina ʻEulopa i koho ʻia Annex 21: ʻO ka hoʻomaʻamaʻa ʻana i nā ʻāina ʻo ʻEulopa ʻaʻohe hapa (2019): Ka pākēneka o ka nui o nā ʻokiʻoki ma ke ʻano o ke kaʻina i ka hoʻohana ʻana i ka toxin EU botulinum. Nā lula Papa 61: Ka nānā 'ana i kēia manawa a me ka wā e hiki mai ana o ka botulinum toxin e ka 'āina 'āina ma 'Eulopa-Palani, Kelemānia, Italia, United Kingdom, Sepania, Rusia a me 'ē a'e o 'Eulopa makeke-kū'oko'a aalysis a me% CAGR o nā kūʻai makahiki (tausani kālā) mai 2020 a 2027 Papa 62: Ka loiloi mōʻaukala o ka botulinum toxin ma ka ʻāina ʻEulopa, Kelemānia, Italia, UK, Sepania, Rusia a me ke koena o ʻEulopa-Kuʻokoʻa ka nānā ʻana o ke kūʻai aku ( tausani dala) a me ka pakeneka ulu makahiki mai 2012 a i 2019 Papa 63: ʻEulopa 15-makahiki botulinum toxin prospect graph graph region by region -2012, 2020 and 2027 France, Germany, Italy, United Kingdom, Spain, Russia and the rest of Europe market. ka haʻihaʻi pākēneka kūʻai waiwai Papa 64: Ka nānā ʻana o ʻEulopa i kēia manawa a me ka wā e hiki mai ana o ka botulinum toxin ma o ka huahana-A Type a me Type B-Ka helu kūʻokoʻa kūʻokoʻa o ka makahiki kūʻai a me ka hui ʻana o ka ulu ʻana o ka makahiki ma nā tausani o nā kālā ʻAmelika mai 2020 a i 2027. Papa 65: Hōʻike mōʻaukala. o Botulinum Toxin Products ma ʻEulopa-Type A a me Type B Markets-I nā makahiki he ʻike kūʻokoʻa kūʻokoʻa o ke kūʻai aku ʻana i kēlā me kēia makahiki ma nā tausani o nā kālā US mai 2012 a 2019 a me% CAGR Papa 66: ʻO ka botulinum toxin 15 makahiki o ʻEulopa.e nānā ma ka huahana-haʻihaʻi waiwai kūʻai o ke ʻano A a me ke ʻano B i 2012, 2020 a me 2027 Pākēneka Papa 67: ʻIke a me ka wā e hiki mai ana o Botulinum Toxin ma ʻEulopa e ka Application-Therapeutics and Aesthetics-Independent Analysis of Annual Sales (Thousand of USD) a me Compound Annual Growth Rate Percentage from 2020 to 2027 Table 68: Botulinum Toxin in Europe Review of the history of toxin applications-therapeutic and aesthetic markers ets-independent analysis of sales (i na tausani o US dollars) mai 2012 a 2019 a me% CAGR Table. 69: 15 mau makahiki o ka noi botulinum toxin i ʻEulopa-2012, 2020 A me 2027 Value Sales Percentage Breakdown of Therapeutics and Aesthetics Table 70: ʻO ka nānā ʻana a me ka wā e hiki mai ana o ka botulinum toxin ma o ka hoʻohana hope ʻana i nā keʻena kūikawā a me dermatology, nā halemai a me nā keʻena lapaʻau. a me nā mea hoʻohana hope ʻē aʻe-no 2020 i ka ʻike kūʻokoʻa o nā kūʻai makahiki makahiki (mau kaukani USD) a me ka pākēneka o ka ulu ʻana o ka makahiki ma 2027 Papa 71: Hōʻike mōʻaukala o ka hoʻohana ʻana i ka Botul.inum Toxin ma Europe-Specialty and Dermatology Clinics, Hospitals and Clinics, and other End-Use Markets-2012 Independent analysis of sales (thanks dollars) to 2019 And% CAGR Table 72: Europe 15-Botulinum Toxin by End Use Year Perspective-2012 , 2020 and 2027 Specialty and Dermatology Clinics, Hospitals and Clinics and Other End Use Value Sales Percentage France Table 73: France Curr Ent and the future analysis of botulinum toxin by product-type A and type B-independent analysis of annual sales (kausani dala) a hui pū ʻia ka pākēneka ulu makahiki mai 2020 a i 2027 Papa 74: ʻO nā huahana botulinum toxin Farani ka loiloi mōʻaukala-Type A a me Type B mākeke-Ka nānā ʻana kūʻokoʻa a me ka% CAGR o ke kūʻai ʻana i kēlā me kēia makahiki (i nā tausani o US) mai 2012 a 2019 Papa 75: Botulinum toxin ma ka huahana ma Palani no 15 makahiki-Kano A a me 2012 Pakeneka o ka haʻihaʻi ʻana o nā kūʻai ʻano B, 2020 a me 2027 Papa 76: Ka nānā ʻana i kēia manawa a me ka wā e hiki mai ana o nā noi botulinum toxin ma Palani-Therapeutics a me Aesthetics-kūʻai makahiki.(tausani dala) a me ka ulu ana o ka makahiki mai ka 2020 a i ka 2027 Ka nana kuokoa o ka helu pakeneka Papa 77: Ka loiloi moolelo no ka noi ana o ka botulinum toxin Farani-Therapeutics and cosmetology market-Ka helu kuokoa o na kuai (tausani dala) mai 2012 a 2019 a me% CAGR Papa 78 : Kaʻiʻo Farani no 15 mau makahiki No ka noi ʻana o ka botulinum toxin-Therapeutics a me ka cosmetology kūʻai waiwai breakdown table 79: ʻO ka nānā ʻana o Farani i kēia manawa a me ka wā e hiki mai ana o ka botulinum toxin ma ka hoʻohana hope ʻana ma 2012, 2020 a me 2027-nā loea a me nā keʻena dermatology, nā haukapila a me nā hopena ʻē aʻe. -hoʻohana-kūʻokoʻa ka nānā ʻana o nā kūʻai kūʻai makahiki (i nā kaukani US) a me nā pākēneka o ka ulu ʻana o ka makahiki mai 2020 a i 2027. Papa 80: ka mōʻaukala Farani o ka botulinum toxin ma ka hoʻohana hope-kūikawā a me nā dermatology Clinics, nā halemai a me nā hale lapaʻau a me nā hopena ʻē aʻe- e hoʻohana i nā mākeke kūʻokoʻa kūʻokoʻa o ke kūʻai aku ʻana i nā makahiki he mau tausani kālā a me ka% CAGR mai 2012 a 2019 Papa 81: ʻO ka nānā ʻana o ka botulinum toxin 15 makahiki o Farani ehope-hoʻohana-Specialties a me ka ili ma 2012 Paneka o ka haʻihaʻi waiwai kūʻai o nā keʻena lapaʻau, nā halemai a me nā keʻena lapaʻau, a me nā mea hoʻohana hope ʻē aʻe, 2020 a me 2027 Kelemānia Papa 82: Ka nānā ʻana a me ka wā e hiki mai ana o ka botulinum toxin e ka huahana ma Germany-Type A a ʻAno B-no 2020 ʻIke kūʻokoʻa kūʻai kūʻai makahiki (i nā kaukani US) a me% CAGR Papa 83 a i 2027: He loiloi mōʻaukala o nā huahana botulinum toxin ma Kelemania-Type A a me Type B market-kūʻai makahiki mai 2012 a 2019 ( i loko o nā tausani o ka US dala) Papa 84: 15-makahiki outlook no German botulinum toxin huahana-breakdown pakeneka o type A a me type B kuai ma 2012, 2020 a me 2027 Papa 85: German iʻo ma ka noi I kēia manawa a me ka wā e hiki mai ana o nā toxins-therapeutics a aesthetics-2020 Nānā kūʻokoʻa o nā kūʻai makahiki (i nā kaukani US) i 2027 a me% CAGR Papa 86: Ka loiloi mōʻaukala o ka noi ʻana o ka botulinum toxin ma Kelemania-Therapeutic and beauty market-Ke kūʻai aku i nā makahiki (i nā kaukani US) mai 2012 i 2019 Indka nānā 'ana a me ka% CAGR Papa 87: 15-makahiki outlook no ka botulinum toxin ma Germany breakdown e ka noi-2012, 2020 a me 2027 waiwai o ka therapeutics a me ka cosmetology kuai pākēneka Papa 88: I kēia manawa a me ka wā e hiki mai botulinum toxin ma Germany Ka ho'āʻo hope o nā toxins-hoʻohana- nā keʻena lapaʻau kūikawā a me nā dermatological, nā halemai a me nā keʻena olakino a me nā hoʻohana hope ʻē aʻe-ka nānā kūʻokoʻa kūʻokoʻa o nā kūʻai makahiki (i nā tausani o nā kālā US) mai 2020 a 2027 a me% CAGR Papa 89: German botulinum toxin e ka loiloi mōʻaukala o ka hoʻohana hope ʻana-ʻoihana a dermatological. nā keʻena lapaʻau, nā halemai a me nā keʻena lapaʻau, a me nā mākeke hoʻohana hope-kūʻokoʻa kūʻokoʻa o ke kūʻai aku (i loko o nā tausani o nā kālā US) mai 2012 a 2019 a me% CAGR Papa 90: Ke hoʻohana hope ʻana o Kelemania he 15 mau makahiki. 2012, 2020 a me 2027 kūʻai aku i nā keʻena lapaʻau kūikawā a me nā dermatological, nā halemai a me nā keʻena lapaʻau a me nā mea hoʻohana hope ʻē aʻe Italia Papa 91: ʻO Italia a me ka wā e hiki mai ana o ka botulinum toxin e ka huahana Analysis-Type A a me Type B-Ka Hoʻohālikelike Kūʻokoʻa o nā Kūʻai Makahiki ma nā tausani o USD a me% CAGR mai 2020 a 2027 Papa 92: Hōʻikeʻike mōʻaukala o Botulinum Toxin e nā huahana ma Italia-Type A a me Type B Markets-2012 Ka nānā ʻana kūʻokoʻa o nā kūʻai makahiki i nā tausani o nā kālā US. i 20 makahiki 19 a me% CAGR Papa 93: ʻO ka 15-makahiki botulinum toxin outlook o Italia ma o ka hoʻopau ʻana o ka waiwai kūʻai o ke ʻano A a me ke ʻano B ma 2012, 2020 a me 2027 Pākēneka papa 94: ʻO ka loiloi o Italia a me ka wā e hiki mai ana o ka botulinum toxin ma o ka noi. -Therapeutics and Aesthetics-Independent analysis of annual sales in thousands of dollars from 2020 to 2027 and% CAGR Table 95: Italia ma o ka noi ʻana ʻO ka loiloi mōʻaukala o botulinum toxin-therapeutics a me ka aesthetics mākeke kūʻokoʻa kūʻokoʻa kūʻai kūʻai makahiki i nā tausani kālā mai 2012 a 2019 a me% CAGR Papa 96: ʻO ka noi noi botulinum toxin 15 mau makahiki o Italia-2012, 2020 a me 2027 ka pākēneka o ka kūʻai aku ʻana o ka Therapeutics a me nā lāʻau Aesthetic Papa 97: Ka nānā ʻana o kēia manawa a me ka wā e hiki mai ana.Hoʻohana Hoʻohana ʻo Botox-Specialty and Dermatology Clinics, Hospitals and Clinics, a me nā mea hoʻohana hope ʻē aʻe-Ka kūʻai ʻana i ka makahiki mai 2020 a 2027 ( Ka nānā ʻana kūʻokoʻa a me ka hoʻohui ʻana i ka pākēneka ulu makahiki ma nā tausani o nā kālā US Papa 98: Ka loiloi mōʻaukala o ka botulinum toxin ma ka hoʻohana hope ʻana ma Italia. - nā keʻena lapaʻau kūikawā a me nā dermatological, nā halemai a me nā keʻena a me nā mākeke hoʻohana hope-2012 a 2019 ʻO ke kūʻai aku makahiki (i nā tausani o nā kālā US) a me ka hoʻohui ʻana i ka nui o ka ulu ʻana o ka makahiki Statistic Analysis Form 99: Italia 15-Annual Outlook no Botulinum Toxin e ka hoʻohana hope- Ka pākēneka o ka waiwai kūʻai o nā keʻena kūikawā a me nā Dermatology, nā halemai a me nā hoʻohana hope ʻē aʻe ma 2012, 2020 a me 2027 Breakdown of UK Market Overview Snapshot Table 100: UK i kēia manawa a me ka nānā ʻana o ka botulinum toxin e ka huahana-type A a me ka nānā kūʻokoʻa B. o ke kuai makahiki (tausani dala) a me ka huina o ka ulu ana o ka makahiki mai 2020 a i 2027. Papa 101: UK e kue ana i ka botulinum Historical Review of Toxin Products-Type A and Type B Markets-2012i ka 2019 Annual Sales (Mulsand of USD) and Compound Annual Growth Rate Percentage Independent Analysis Table 102: Botulinum Toxin by Product in the UK for 15 Years-2 Paneka ka haʻihaʻi o ka makahiki kūʻai o ke ʻano A a me ke ʻano B 012, 2020 a me 2027 Papa 103 : Ka nānā 'ana i kēia manawa a me ka wā e hiki mai ana o nā noi botulinum toxin ma United Kingdom-Therapeutics and Aesthetics-Annual sales from 2020 to 2027 (mau tausani dala) Ka ho'oka'awale kū'oko'a o ka pākēneka a me ka ho'ohuihui makahiki ulu ulu 104: Ka loiloi mō'aukala o British botulinum toxin e ka noi-Therapeutics a me ka cosmetology market-Ka helu kūʻokoʻa a me ka% CAGR o ke kūʻai aku i kēlā me kēia makahiki (i nā kaukani US) mai 2012 a 2019 Papa 105: ʻO ka nānā ʻana o ka botulinum toxin ma o ka noi ʻana ma UK ma 2015-Therapeutics a me ka cosmetology breakdown e ka pakeneka o ke kūʻai aku no 2012, 2020 a me 2027 Papa 106: ʻO ka ʻiʻo UK ma ka hoʻohana hope ʻO ka nānā ʻana i kēia manawa a me ka wā e hiki mai ana o nā toxin-specialist and dermatological clinics, hospitals and clinics, and other end-use-ind.ka nānā ʻana o ke kūʻai aku (i nā tausani o nā kālā US) mai 2020 a 2020 2027 a me% CAGR Papa 107: UK Press Hoʻohana hope moʻolelo o ka botulinum toxin-specialist and dermatological clinics, hospitals and clinics, and other end-use market-independent analysis o nā kūʻai makahiki (i nā kaukani US) a me% CAGR mai 2012 a 2019 Papa 108: UK Prospects no ka hoʻohana hope ʻana i ka botulinum toxin i nā makahiki 15-ka loea a me nā keʻena dermatological, nā halemai a me nā keʻena, a me nā helu kūʻai waiwai kūʻai hope 2012 , 2020 a me 2027 Sepania Papa 109: ʻO ka botulinum toxin o kēia manawa ma ka huahana ma Sepania Ka nānā ʻana i ka wā e hiki mai ana-Type A a me Type B-Ka helu kūʻokoʻa kūʻokoʻa o nā kūʻai kūʻai makahiki (i loko o nā kaukani US) a me ka pākēneka ulu makahiki hui mai 2020 a 2027 Papa 110: ʻO ka loiloi mōʻaukala o ka botulinum toxin e ka huahana ma Sepania-Type A A me Type B market-ka nānā kūʻokoʻa a me ka% CAGR o ke kūʻai aku (i nā tausani o nā kālā US) mai 2012 a 2019 Papa 111: Botulinum toxin e ka huahana ma Sepania i 15 mau makahiki-haʻihaʻi e. waiwaie pākēneka 2012, 2020 a me 2027 Kūʻai Papa 112 no ke ʻano A a me ke ʻano B: I kēia manawa a me ka noi ʻana o Botox ma Sepania Ka ʻike ʻana o nā Toxins-Therapeutics a me Aesthetics-Kuʻokoʻa kūʻokoʻa a me ka% CAGR o nā kūʻai makahiki (i nā kaukani US) mai 2020 to 2027 Table 113: Historical Review of the Use of Botulinum Toxin in Spain-Therapeutics and Aesthetics Market- Independent analysis of annual sales (in thousands of US dollars) and% CAGR from 2012 to 2019 Table 114: The application prospects of botulinum toxin in Spain in 15 years-the sales value of therapeutic drugs and cosmetic drugs in 2012, 2020 and 2027 Percentage Current Table 115: Spain and Future Analysis of Botulinum Toxin by End Use-Specialty and Dermatology Clinics, Hospitals and Clinics and Other End Uses- For 2020-2027 Annual Sales (Thousands of US Dollars) and Compound Years Independent Analysis of Growth Rate Percent Table 116: Historical Review of Spain Botulinum Toxin by End Use-Specialty and Dermatology Clinics, Hos
Hoʻomaka ka papaʻai meaʻai a ka poʻe hoʻomaka mai nā kumu kumu a hōʻike iā ʻoe i ke ʻano o ka ʻai diabetic olakino a hoʻomaha no hoʻokahi pule.Inā ua ʻike ʻia ʻoe a i ʻole e loaʻa ana i ka maʻi diabetes no nā makahiki he nui, e ʻike ʻoe i ka nui o ka hoʻoikaika ʻana no ka ʻai olakino ma aneʻi.
ʻO kēia ka hōʻuluʻulu o kekahi o nā noiʻi ʻepekema hou loa e pili ana i ka coronavirus hou, a me nā hoʻoikaika ʻana e ʻimi i nā lāʻau lapaʻau a me nā kano no COVID-19 (he maʻi i hoʻokumu ʻia e ka maʻi).Hoʻomaopopo nā ʻike hou i ke kumu o nā maʻi maʻi maʻi maʻi e keʻakeʻa ana i nā alaloa - e like me ka bronchitis maʻi, emphysema, a me ka pulmonary fibrosis - e hoʻonui ai i ka pilikia o ka COVID-19.Ua hōʻike nā mea noiʻi ma ka "Nature Communications" https://go.nature.com/3kmjsYy i ka Pōʻakolu e hoʻololi kēia mau maʻi i nā hoʻololi genetic i nā epithelial cell airway, e hoʻolilo ana i nā cell i mea palupalu i ka hoʻouka coronavirus.
Wahi a ka hui noiʻi, ua helu ʻo Xiaomi i ka lua me ka 17% kahele o nā moku kelepona honua no ka manawa mua, kahi piʻi o 3% mai ka hapaha mua.I ka lua o ka hapaha, ua hoʻonui ʻia ka hoʻouna ʻana o nā kelepona honua e 12%, me Samsung Electronics e alakaʻi ana me ka 19% kahele, a ʻo Apple ke kūlana kolu me ka 14% mahele.Ua ʻōlelo ka luna noiʻi ʻo Canalys ʻo Ben Stanton, ʻo ke kumukūʻai kūʻai maʻamau o nā kelepona paʻa Xiaomi he 40% a 75% ʻoi aku ka liʻiliʻi ma mua o Samsung a me Apple, a ua hoʻohui ʻia ʻo Xiaomi ka mea nui i kēia makahiki ʻo ia ka hoʻonui ʻana i ke kūʻai aku o kāna mau mea kiʻekiʻe.
Hoʻokahi manawa i ka pule, lawe ʻo Ghulam Ahmed, 38 makahiki i kāna ʻoihana kūkākūkā cryptocurrency e komo i kahi hui WhatsApp me nā haneli o nā lālā e makemake nui e aʻo pehea e mine a kālepa cryptocurrency ma Pakistan.Ua haʻalele ʻo Ahmed, 38, i kāna hana ma 2014. Manaʻo ʻo ia ʻoi aku ka maikaʻi o ka mining Bitcoin.Ua ʻōlelo ʻo ia: "Ke wehe wau i kahi hālāwai e nīnau i nā nīnau, loaʻa iaʻu nā ʻike he nui a e hoʻolimalima wau i nā hola e pane ai iā lākou., E aʻo iā lākou i ke kumu o ka cryptocurrency."Ua ʻike ʻo Pakistan i ka pōmaikaʻi o ke kālepa cryptocurrency a me ka mining.Ua hoihoi ka poʻe i nā mano o nā manaʻo o nā wikiō e pili ana ma ka pāpili kaiaulu a me nā kālepa ma nā hoʻololi pūnaewele.
Ua hōʻike ʻo Pelekikena Federal Reserve ʻo Jerome Powell i ka US Senate e pili ana i ka hoʻonui ʻana a me ka hiki ke hoʻokomo ʻia o ke kālā kikohoʻe.
(Bloomberg)-Ua hoʻoneʻe nā nalu wela ma kekahi o nā panalāʻau ʻoihana nui loa o Kina i ka hoʻohana ʻana i ka mana kūloko i nā pae i ʻike ʻole ʻia a hoʻokau i nā lānahu wela e hiki ke hoʻopaʻa i nā kiʻekiʻe.ʻO ka ukana uila o Zhejiang, kahi moku hikina kokoke i Shanghai, ʻoi aku ma mua o 100 miliona kilowatts i kēlā me kēia hola.Ma ka Poalua, ua ʻōlelo ʻo State Grid i kāna nūpepa no ka manawa mua.ʻO ka hoʻohana ʻana i Jiangsu kokoke a me Guangdong hema i hoʻopaʻa ʻia i kahi moʻolelo kiʻekiʻe, kahi kiʻekiʻe ka wela o 37 degere.
Ma hope o ka hāʻule ʻana no ʻehā mau lā, ua piʻi hou ke kumukūʻai o AMC i 1.7% i $33.99.Ma ka manawa like, ua hoʻomau ke kumukūʻai o ka mea kūʻai pāʻani wikiō ʻo GameStop i kona emi ʻana i kēia manawa, hāʻule 3.1% i US $162.34, mai kahi kiʻekiʻe o US $ 344.66 i Iune.Ua ʻōlelo ʻo Netflix i ka pō Pōʻakolu ua hoʻolimalima ʻo ia i kahi luna Facebook mua e alakaʻi i kāna māhele pāʻani wikiō no ka mea ke hoʻonui nei i kāna mau hana ma mua o ka ʻoihana streaming kuʻuna, hiki ke hoʻonui i ka hoʻokūkū no GameStop.
Ua hoʻololi ka noi brokerage Robinhood i ke kālepa kūʻai.Ua wehewehe ka Wall Street Journal i nā kumu o kona piʻi ʻana i ke ʻano o nā hoʻokolokolo kānāwai a me nā pilikia hoʻoponopono, ʻoiai ke nānā nei i kahi IPO.Palapala Kiʻi: Jacob Breynolds/Wall Street Journal
Ua ʻōlelo ka Fed i ka Pōʻalima ua hāʻule ka huahana hana i ka 0.1% i ka mahina i hala, ma hope o ka piʻi ʻana o 0.9% i Mei.Ua wānana nā mea hoʻokele waiwai i noiʻi ʻia e Reuters e hoʻonui ʻia ka huahana hana e 0.2% i Iune.ʻO ka ʻoihana hana, ʻo ia ka 11.9% o ka hoʻokele waiwai o ʻAmelika, kākoʻo ʻia e ka hoʻoulu ʻana i ke kālā nui, haʻahaʻa haʻahaʻa haʻahaʻa, a hoʻomau i ka koi ikaika no nā waiwai, ʻoiai ke hoʻihoʻi ʻia ka hoʻolilo ʻana i ka ʻoihana lawelawe.
ʻOiai ka piʻi ʻana o ke koi kinoea a me nā kumukūʻai ma ʻEulopa, ua hōʻole ka mokuʻāina mokuʻāina ʻo Rūsia e hāʻawi i nā mea kūʻai aku i ke kinoea hou.
STOCKHOLM (Reuters)-Ua hoʻolaha ʻo Ericsson o Suedena i ka Pōʻalima ʻo kāna mau kālā kumu no ka hapaha ʻelua he haʻahaʻa ma mua o nā manaʻo o ka mākeke, ʻoiai ʻo ke kūʻai ikaika ʻana o nā lako 5G i ka hapa nui o nā mākeke i hoʻopau ʻia e ka emi ʻana o ke kūʻai aku ma ka ʻāina nui o Kina.He mea hoʻokūkū kēia mea hana kelepona ʻo Huawei Technologies Co., Ltd. a me ka Nokia o Finland.Ua haule kona huina kuai mai 55,6 billion Swedish kronor (6,3 billion US dollars) i 54,9 billion Swedish krona (6,3 billion US dollars) no ka manawa mua i loko oʻekolu makahiki, i emi iho ma mua o Analysts manaoia 57,2 billion Swedish kronor.
(Bloomberg) -Britishvolt Ltd., ka mea e kokoke ana e hoʻomaka i ke kūkulu ʻana i ka hale hana pākaukau nunui mua o UK, ke noʻonoʻo nei i ka papa inoa ʻana ma ka London Stock Exchange e loaʻa kālā kēia papahana £2.6 biliona (US $ 3.6 biliona), hiki ke kōkua i ke UK e hoʻomohala i ke kī.ʻO ka mea hoʻokumu a me ka Luna Hoʻokele o Britishvolt ʻo Orral Nadjari i ʻōlelo i loko o kahi hālāwai ninaninau e hoʻoholo ʻo ia inā e papa inoa ma Lākana a i New York i loko o ʻekolu mahina.No ka hui
Ua hōʻike ʻia ka ʻikepili i kiʻi ʻia mai ka Energy Information Administration ua hoʻonui ʻia nā mea waiwai ʻaila US ma mua o 1 miliona mau barela i ka pule i hala.
Ma ka pūnaewele a i ʻole ka hui kumu kumu ʻoihana kino, kūpono no ka hoʻopaʻa inoa ʻoihana āpau, nā hana moʻomeheu manuahi i kēlā me kēia manawa, ʻike i nā kuʻuna aupuni like ʻole, Prince Tuen Mun Yuen Long Tin Shui Wai Sha Tin Wind Class!
(Bloomberg)-ʻO ka hoʻoholo a Brookfield Infrastructure Partners LP e hoʻonui i kāna kālā kūʻē a me ka hāʻawi kālā iā Canadian Inter Pipeline Ltd. i 8.6 biliona kālā Kanada (6.9 biliona kālā ʻAmelika) ua hoʻololi i ka manaʻo e hoʻokūkū iā Pembina Pipeline Corp. Ua piʻi aʻe ke kumukūʻai o ka hui waena waena.Ua ʻae ʻo Brookfield Infrastructure Corporation e hoʻonui i ka ʻāpana kālā o kāna hāʻawi ʻana ma 2.6% a i $20 no kēlā me kēia mahele Inter Pipeline i mea e hoʻoikaika hou ai e uhaki i ka loaʻa ʻana o nā ʻāpana āpau a Pembina.Koho kālā
Iulai 14-Ua kamaʻilio ʻo Tobias Levkovich, ke poʻo o Citi US equity strategist, me Alix Steel a me Guy Johnson o Bloomberg e pili ana i nā manaʻo hoʻonui i ka "Bloomberg Market".
E hoemi i na koina.E ʻike i ka nui āu e mālama ai me Saxo.Aia nā pilikia ma ke kālepa mea hana kālā.
(Bloomberg) - He opaque ka hana o China Huarong Asset Management Co., Ltd. ma mua o ʻekolu mau mahina ma hope o ka hoʻopanee ʻana o kāna hana i 2020, ka mea i hoʻoulu ai i nā loli nui i nā paʻa hui a me nā kuhi e pili ana i kona wā e hiki mai ana.ʻO ka nūhou hou loa e pili ana i ka hui ʻaʻohe nūhou paʻa.Ke uku nei nā luna ʻaiʻē maikaʻi ʻole i nā palapala paʻa.Ua hōʻike ʻia ʻo Bloomberg News i ka hopena o Iune e koi ana ke aupuni i kekahi o nā hui ʻoihana mokuʻāina nui loa o Kina, ʻo CITIC Group, e nānā i ke kūlana kālā o Kina Huarong.I ka manawa like,
(Bloomberg)–E kūʻai aku ana ʻo Leslie Wexner ma kahi o $745 miliona o nā ʻāpana ma L Brands Inc., ʻo ia hoʻi ka Victoria's Secret a me Bath & Body Works Stock kūʻai i loko o ka hui lole e hōʻea i ka US $ 1.2 biliona ma 2021. Wahi a kahi hoʻopiʻi hoʻoponopono i ka Pōʻalima , Ke kūʻai aku nei ka billionaire i nā ʻāpana o ka Columbus, Ohio-based retailer ma o kahi makana lua i mālama ʻia e JPMorgan Chase.E hoʻopau ke kūʻai aku ma Iulai 19. Ua haʻalele ʻo Wexner 83 makahiki mai ka papa alakaʻi o L Brand.
Ua piʻi ka paona i ke kālā i ka Pōʻakolu, no ka mea, ʻoi aku ka nui o ka hoʻonui ʻana ma UK i nā mea i manaʻo ʻia i ka pae kiʻekiʻe ma kahi o ʻekolu mau makahiki, e hoʻāla ana i ka manaʻo e noʻonoʻo mua ka Bank of England inā e hōʻemi i kāna hoʻolālā hoʻoulu nui.ʻO ka hoʻonuiʻana i ka mahinaʻo Iune iʻoi aʻe ma mua o ka Bank of England's 2% target, hiki i ka 2.5%, ke kiʻekiʻe kiʻekiʻe loa maiʻAukake 2018. I ka paneʻana, ua piʻi ka paona i ka 0.5% i $ 1.3889, e hoʻomau ana i nā lanakila o ke kakahiaka.